Detail

Study ID: Vyriad Regeneron VYR-VSV2-203 Voyager V1

Title:

Phase 2 Trial of Voyager V1 (Vesicular Stomatitis Virus Expressing NIS and Human Interferon Beta, VV1), in Combination with Cemiplimab in patients with Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Melanoma or Endometrioid Endometrial Carcinoma

Description:
Title: Early Phase Clinical Trial of combination Voyager V1 with Cemiplimab for patients diagnosed with Hepatocellular Carcinoma (liver), Non-Small Cell Lung Cancer, Melanoma (skin), or Endometrioid Endometrial Carcinoma (female reproductive organs) Description: This is an early phase clinical trial (Phase 2) of a drug called Voyager V1. In addition to the study drug you will also be administered Cemiplimab. This study is designed for patients diagnosed with Hepatocellular Carcinoma (liver), Non-Small Cell Lung Cancer, Melanoma (skin) or Endometrioid Endometrial Carcinoma (female reproductive organs) You must meet the below criteria at least to be considered for study participation. Your physician will review more entry criteria with you in person.  >18 yo  You must be diagnosed with: HCC, Melanoma, NSCLC, Endometrial  We must be able to measure your disease
Location:
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Disease:
Endometrial, HEP (Liver Tumors), Melanoma, Non-Small Cell Lung Cancer
Stage:
Phase II
Status:
Active - Open to Accrual